Pharmacogenetics of minimal residual disease response in children with B-precursor acute lymphoblastic leukemia: A report from the children's oncology group

Stella M. Davies, Michael J Borowitz, Gary Rosner, Kristin Ritz, Meenakshi Devidas, Naomi Winick, Paul L. Martin, Paul Bowman, James Elliott, Cheryl Willman, Soma Das, Edwin H. Cook, Mary V. Relling

Research output: Contribution to journalArticle

Abstract

Minimal residual disease (MRD) as a marker of antileukemic drug efficacy is being used to assess risk status and, in some cases, to adjust the intensity of therapy. Within known prognostic categories, the determinants of MRD are not known. We measured MRD by flow cytometry at day 8 (in blood) and at day 28 (in bone marrow) of induction therapy in more than 1000 children enrolled in Pediatric Oncology Group therapy protocols 9904, 9905, and 9906. We classified patients as "best risk" if they had cleared MRD by day 8 of therapy and as "worst risk" if they had MRD remaining in bone marrow at day 28, and tested whether MRD was related to polymorphisms in 16 loci in genes hypothesized to influence response to therapy in acute lymphoblastic leukemia (ALL). After adjusting for known prognostic features such as presence of the TEL-AML1 rearrangement, National Cancer Institute (NCI) risk status, ploidy, and race, the G allele of a common polymorphism in chemokine receptor 5 (CCR5) was associated with more favorable MRD status than the A allele (P = .009, logistic regression), when comparing "best" and "worst" risk groups. These data are consistent with growing evidence that both acquired and host genetics influence response to cancer therapy.

Original languageEnglish (US)
Pages (from-to)2984-2990
Number of pages7
JournalBlood
Volume111
Issue number6
DOIs
StatePublished - Mar 15 2008

Fingerprint

Oncology
Pharmacogenetics
Residual Neoplasm
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Polymorphism
Bone
Bone Marrow
Alleles
Therapeutics
Pediatrics
National Cancer Institute (U.S.)
Flow cytometry
Ploidies
Chemokine Receptors
Group Psychotherapy
Logistics
Flow Cytometry
Blood
Genes
Logistic Models

ASJC Scopus subject areas

  • Hematology
  • Biochemistry
  • Cell Biology
  • Immunology

Cite this

Pharmacogenetics of minimal residual disease response in children with B-precursor acute lymphoblastic leukemia : A report from the children's oncology group. / Davies, Stella M.; Borowitz, Michael J; Rosner, Gary; Ritz, Kristin; Devidas, Meenakshi; Winick, Naomi; Martin, Paul L.; Bowman, Paul; Elliott, James; Willman, Cheryl; Das, Soma; Cook, Edwin H.; Relling, Mary V.

In: Blood, Vol. 111, No. 6, 15.03.2008, p. 2984-2990.

Research output: Contribution to journalArticle

Davies, SM, Borowitz, MJ, Rosner, G, Ritz, K, Devidas, M, Winick, N, Martin, PL, Bowman, P, Elliott, J, Willman, C, Das, S, Cook, EH & Relling, MV 2008, 'Pharmacogenetics of minimal residual disease response in children with B-precursor acute lymphoblastic leukemia: A report from the children's oncology group', Blood, vol. 111, no. 6, pp. 2984-2990. https://doi.org/10.1182/blood-2007-09-114082
Davies, Stella M. ; Borowitz, Michael J ; Rosner, Gary ; Ritz, Kristin ; Devidas, Meenakshi ; Winick, Naomi ; Martin, Paul L. ; Bowman, Paul ; Elliott, James ; Willman, Cheryl ; Das, Soma ; Cook, Edwin H. ; Relling, Mary V. / Pharmacogenetics of minimal residual disease response in children with B-precursor acute lymphoblastic leukemia : A report from the children's oncology group. In: Blood. 2008 ; Vol. 111, No. 6. pp. 2984-2990.
@article{0bfa07509909470ab1225e84cfa811b8,
title = "Pharmacogenetics of minimal residual disease response in children with B-precursor acute lymphoblastic leukemia: A report from the children's oncology group",
abstract = "Minimal residual disease (MRD) as a marker of antileukemic drug efficacy is being used to assess risk status and, in some cases, to adjust the intensity of therapy. Within known prognostic categories, the determinants of MRD are not known. We measured MRD by flow cytometry at day 8 (in blood) and at day 28 (in bone marrow) of induction therapy in more than 1000 children enrolled in Pediatric Oncology Group therapy protocols 9904, 9905, and 9906. We classified patients as {"}best risk{"} if they had cleared MRD by day 8 of therapy and as {"}worst risk{"} if they had MRD remaining in bone marrow at day 28, and tested whether MRD was related to polymorphisms in 16 loci in genes hypothesized to influence response to therapy in acute lymphoblastic leukemia (ALL). After adjusting for known prognostic features such as presence of the TEL-AML1 rearrangement, National Cancer Institute (NCI) risk status, ploidy, and race, the G allele of a common polymorphism in chemokine receptor 5 (CCR5) was associated with more favorable MRD status than the A allele (P = .009, logistic regression), when comparing {"}best{"} and {"}worst{"} risk groups. These data are consistent with growing evidence that both acquired and host genetics influence response to cancer therapy.",
author = "Davies, {Stella M.} and Borowitz, {Michael J} and Gary Rosner and Kristin Ritz and Meenakshi Devidas and Naomi Winick and Martin, {Paul L.} and Paul Bowman and James Elliott and Cheryl Willman and Soma Das and Cook, {Edwin H.} and Relling, {Mary V.}",
year = "2008",
month = "3",
day = "15",
doi = "10.1182/blood-2007-09-114082",
language = "English (US)",
volume = "111",
pages = "2984--2990",
journal = "Blood",
issn = "0006-4971",
publisher = "American Society of Hematology",
number = "6",

}

TY - JOUR

T1 - Pharmacogenetics of minimal residual disease response in children with B-precursor acute lymphoblastic leukemia

T2 - A report from the children's oncology group

AU - Davies, Stella M.

AU - Borowitz, Michael J

AU - Rosner, Gary

AU - Ritz, Kristin

AU - Devidas, Meenakshi

AU - Winick, Naomi

AU - Martin, Paul L.

AU - Bowman, Paul

AU - Elliott, James

AU - Willman, Cheryl

AU - Das, Soma

AU - Cook, Edwin H.

AU - Relling, Mary V.

PY - 2008/3/15

Y1 - 2008/3/15

N2 - Minimal residual disease (MRD) as a marker of antileukemic drug efficacy is being used to assess risk status and, in some cases, to adjust the intensity of therapy. Within known prognostic categories, the determinants of MRD are not known. We measured MRD by flow cytometry at day 8 (in blood) and at day 28 (in bone marrow) of induction therapy in more than 1000 children enrolled in Pediatric Oncology Group therapy protocols 9904, 9905, and 9906. We classified patients as "best risk" if they had cleared MRD by day 8 of therapy and as "worst risk" if they had MRD remaining in bone marrow at day 28, and tested whether MRD was related to polymorphisms in 16 loci in genes hypothesized to influence response to therapy in acute lymphoblastic leukemia (ALL). After adjusting for known prognostic features such as presence of the TEL-AML1 rearrangement, National Cancer Institute (NCI) risk status, ploidy, and race, the G allele of a common polymorphism in chemokine receptor 5 (CCR5) was associated with more favorable MRD status than the A allele (P = .009, logistic regression), when comparing "best" and "worst" risk groups. These data are consistent with growing evidence that both acquired and host genetics influence response to cancer therapy.

AB - Minimal residual disease (MRD) as a marker of antileukemic drug efficacy is being used to assess risk status and, in some cases, to adjust the intensity of therapy. Within known prognostic categories, the determinants of MRD are not known. We measured MRD by flow cytometry at day 8 (in blood) and at day 28 (in bone marrow) of induction therapy in more than 1000 children enrolled in Pediatric Oncology Group therapy protocols 9904, 9905, and 9906. We classified patients as "best risk" if they had cleared MRD by day 8 of therapy and as "worst risk" if they had MRD remaining in bone marrow at day 28, and tested whether MRD was related to polymorphisms in 16 loci in genes hypothesized to influence response to therapy in acute lymphoblastic leukemia (ALL). After adjusting for known prognostic features such as presence of the TEL-AML1 rearrangement, National Cancer Institute (NCI) risk status, ploidy, and race, the G allele of a common polymorphism in chemokine receptor 5 (CCR5) was associated with more favorable MRD status than the A allele (P = .009, logistic regression), when comparing "best" and "worst" risk groups. These data are consistent with growing evidence that both acquired and host genetics influence response to cancer therapy.

UR - http://www.scopus.com/inward/record.url?scp=42449157637&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=42449157637&partnerID=8YFLogxK

U2 - 10.1182/blood-2007-09-114082

DO - 10.1182/blood-2007-09-114082

M3 - Article

C2 - 18182569

AN - SCOPUS:42449157637

VL - 111

SP - 2984

EP - 2990

JO - Blood

JF - Blood

SN - 0006-4971

IS - 6

ER -